PH
PHPN.F Galectin Therapeutics Inc
- Market cap
- EUR 296M
- P/E
- -
- P/B
- 217.35x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is PHPN.F undervalued?
Graham numberThe Graham number of Galectin Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Galectin Therapeutics Inc fundamental analysis
No fundamental analysis for Galectin Therapeutics Inc yet.
Galectin Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Galectin Therapeutics Inc
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension. It has a joint venture co-owned by SBH Sciences, Inc…
Full company profileGalectin Therapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Galectin Therapeutics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | - | - | - | - | - | - | - | - |
| Operating Income | -21.5M | -16.2M | -13.6M | -13.4M | -23.4M | -30.2M | -38.4M | -38.1M | -42.4M | -20.1M | -16.1M |
| EBITDA | - | -16.2M | -13.6M | -13.2M | -23.3M | -30.0M | -37.7M | -38.2M | -41.5M | -23.5M | -20.3M |
| Net Income | -21.4M | -16.2M | -13.9M | -13.3M | -23.5M | -30.5M | -38.8M | -41.1M | -47.0M | -30.8M | -28.3M |
| EPS | - | -0.45 | -0.34 | -0.23 | -0.41 | -0.51 | -0.65 | -0.66 | -0.74 | -0.47 | -0.43 |
| Balance Sheet | |||||||||||
| Total Assets | 15.8M | 4.16M | 9.01M | 48.5M | 29.6M | 41.8M | 21.3M | 28.2M | 17.5M | 19.5M | 14.8M |
| Total Liabilities | 3.78M | 2.97M | 2.11M | 2.87M | 5.41M | 39.2M | 55.2M | 88.4M | 121M | 146M | 152M |
| Shareholders' Equity | 12.0M | 1.19M | 6.90M | 45.6M | 24.2M | 2.62M | -33.9M | -60.2M | -103M | -126M | -137M |
| Cash & Short-term Investments | 15.4M | 3.05M | 8.25M | 47.5M | 27.1M | 39.6M | 18.6M | 25.7M | 15.1M | 17.7M | 13.3M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -16.4M | -15.9M | -10.2M | -10.8M | -20.6M | -24.3M | -31.1M | -33.0M | -41.8M | -23.9M | -12.6M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | - | -15.9M | -10.2M | -10.8M | -20.6M | -24.3M | -31.1M | -33.0M | -41.8M | -23.9M | -12.6M |
| Ratios | |||||||||||
| ROE | -178.4% | -1,360.9% | -201.5% | -29.2% | -97.0% | -1,166.9% | - | - | - | - | - |
| ROA | -135.7% | -390.2% | -154.3% | -27.4% | -79.3% | -73.0% | -182.2% | -145.6% | -268.9% | -157.9% | -191.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
Galectin Therapeutics Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | USD 394K | 0.01 | - |
| 2018 | USD 394K | 0.01 | - |
| 2017 | USD 394K | 0.01 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:6 on Mar 23, 2012.
Who owns Galectin Therapeutics Inc
- Insiders 52.80%
- Institutions 15.72%
- Public & others 31.49%
- Shares outstanding 101M
- Free float 47.9M
Galectin Therapeutics Inc company profile
- Company name
- Galectin Therapeutics Inc
- Ticker
- PHPN.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 9
- Fiscal year end
- December
- Address
- 4960 Peachtree Industrial Boulevard, Norcross, GA, United States, 30071
- Phone
- 678 620 3186
- Website
- galectintherapeutics.com
About Galectin Therapeutics Inc
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension. It has a joint venture co-owned by SBH Sciences, Inc. to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
Galectin Therapeutics Inc management
6- Mr. Joel Lewis CPAPresident & CEO · born 1970
- Mr. Jack W. Callicutt CPACFO, Treasurer & Corporate Secretary · born 1967
- Dr. Khurram Jamil M.D.Chief Medical Officer · born 1976
- Mr. Robert Tritt J.D.General Counsel
- Mr. Jim Wilkins Ph.D.Head of CMC & Pharmaceutical Development
- Ms. Beth KnowlesExecutive Assistant & Officer Manager